@article{5777bb105050493290646dd685107fc2,
title = "Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma",
abstract = "Patients with squamous cell carcinoma of the head and neck (HNSCC) are usually treated by a multimodal approach with surgery and/or radiochemotherapy as the mainstay of localregional treatment in cases with advanced disease. Both chemotherapy and radiation therapy have the disadvantage of causing severe side effects, while the clinical outcome of patients diagnosed with HNSCC has remained essentially unchanged over the last decade. The potential of immunotherapy is still largely unexplored. Here the authors review the current status of the art and discuss the future challenges in HNSCC treatment and prevention.",
keywords = "CRT, Cancer vaccines, EGFR, HNSCC, HPV",
author = "Christopher Schutt and Klaus Bumm and Leonardo Mirandola and Giovanni Bernardini and Cunha, {Nicholas D.} and Lukman Tijani and Diane Nguyen and Joehassin Cordero and Jenkins, {Marjorie R.} and Everardo Cobos and Kast, {W. Martin} and Maurizio Chiriva-Internati",
note = "Funding Information: Accepted 30 October 2011. Christopher Schutt and Klaus Bumm contributed equally to this article. W. Martin Kast holds the Walter A. Richter Cancer Research Chair. We thank Teri Fields for assistance in revising this manuscript. This review is partially based on research that is supported by NIH grants RC2 CA148298-01 and RO1 CA74397-11 (to WMK). This review has been partially supported by the Associate Dean of the Oncology Programs at TTUHSC. The Billy and Ruby Power Endowment for Cancer Research (MCI) and Laura W. Bush Institute for Women{\textquoteright}s Health(MCI) and Mrs J. Avery “Janie” Rush Endowed Chair for Excellence in WH and Oncology (MCI).",
year = "2012",
month = feb,
doi = "10.3109/08830185.2011.637253",
language = "English (US)",
volume = "31",
pages = "22--42",
journal = "International Reviews of Immunology",
issn = "0883-0185",
publisher = "Informa Healthcare",
number = "1",
}